BIOTRONIK’s DX Technology Reaches Significant Milestone: 100,000 DX Devices Implanted
BIOTRONIK announced the milestone achievement of 100,000 implanted single-chamber implantable cardioverter-defibrillators (ICDs) equipped with DX Technology. Since the introduction of this unique technology in 2009, clinicians in more than 80 countries across all continents use DX ICDs.
“Reaching this significant milestone, BIOTRONIK stands as a proud pioneer and partner in cardiac rhythm management. Our commitment to quality and focus on innovation sets us apart, allowing us to introduce meaningful innovations in the market, such as DX Technology, that make a real difference in patients’ lives,” Dr. Andreas Hecker, President CRM/EP at BIOTRONIK, shares. “This milestone demonstrates our collective efforts and dedication to making a positive difference and helps us define a new standard in patient care.”
What makes DX Technology so distinctive? The incidence of atrial fibrillation (AF) in patients with ICDs is approximately 21 percent (mean annual probability),1 and AF is often undetected – and therefore untreated. Single-chamber ICDs account for a significant proportion of ICDs implanted, which, due to the absence of an atrial lead, cannot provide direct atrial sensing.1 DX Technology, however, available as a single-lead ICD system equipped with a floating atrial dipole, offers reliable, timely information about atrial arrhythmias and detects AF early.2, 3, 4, 5, 6 After detection, the DX ICD system helps monitor AF burden over time3 so that clinicians can intervene when needed, react to changes in patient status and optimize patient treatment. In combination with BIOTRONIK Home Monitoring®, and optionally the BIOTRONIK Patient App, this AF management solution offers a comprehensive assessment of ICD patients and enables earlier, well-informed decision-making.3
“We are deeply grateful for the trust we’ve received from the medical community. We develop solutions to ease physicians’ workloads and improve patient care through holistic and connected approaches. Our innovations are rooted in trustworthy customer relations, feedback and our extensive expertise in cardiac device implants and leads,” says Dr. David Hayes, Chief Medical Officer, BIOTRONIK, Inc. He adds, “With this impressive milestone and the extensive clinical evidence, DX Technology has proven itself, and I am confident that we will reach more milestones such as this in the years to come.”
Over the past decades, more than 20 clinical studies, that enrolled over 4,000 patients, have confirmed the safety and efficacy of DX Technology. This strong foundation of clinical evidence has recently been enriched by the MATRIX study results, the largest clinical evaluation of DX Technology to date. Results from the MATRIX study confirm under real-world conditions that DX, with Home Monitoring, allows for reliable, guideline-recommended remote monitoring of subclinical AF.
BIOTRONIK reaffirms its dedication to innovation and continuous improvement of DX Technology. Having reached the 100,000 milestone sets us on a clear path to further enhancing DX Technology and expanding it to a broader product range – ensuring that more patients can benefit from this cutting-edge technology in the future.
